Bayer says settlements over pulled cholesterol drug total nearly US&#36;1.1B
554464
BERLIN  - Drug maker Bayer AG said Monday it has reached settlements in  more than 2,800 cases related to the 2001 withdrawal of a cholesterol-lowering drug, paying nearly &#36;1.1 billion US in out-of-court deals.
338909
Germany&#39;s Bayer has agreed to sell its blood products business to US investment firms Cerberus and Ampersand Ventures for about $590 million as it continues to narrow the focus of its health-care business.
453569
WASHINGTON Federal regulators are taking another look at its records of a cholesterol drug that was pulled from the market in 2001.
679156
Boston Scientific Corp.  said on Friday it will pay $195 million to settle numerous legal claims related to the recall of implantable heart defibrillators made by Guidant Corp., which it acquired last year.
417734
Heart attack prevention has just taken another step with the US Food and Drug Administration&#39;s go-ahead for one of the nation&#39;s best-selling cholesterol
389904
LOS ANGELES (CBS.MW) - US-traded shares of GlaxoSmithKline were up Thursday as the drugmaker reported a settlement of a lawsuit filed by New York state over disclosure of Paxil test results on minors.
348152
The German drug maker Bayer said its third-quarter profit fell 35 percent on costs related to its acquisition of a rival, Schering, but its performance still exceeded analystsÂ expectations. Bayer earned 320 million euros ($419 million) in the three months through September, down from 493 million euros a year earlier. Sales rose 26 percent, to 7.78 billion euros ($10.2 billion). The company, based in Leverkusen, said it booked special charges totaling 139 million euros ($182 million) in the quarter, with 106 million euros ($139 million) of that mostly attributable to the integration of its health care unit with Schering. Bayer bought Schering in June in a deal worth nearly 16.9 billion euros ($22 billion) to strengthen its health care business. The company said its health care unit was Âthe principal growth engine for BayerÂs business in the third quarter,Â with sales climbing 73 percent, to 3.48 billion euros ($4.56 billion).
621817
Global grocery retailer Ahold NV and its former chief executive have reached settlements with the US Securities and Exchange Commission over charges related to a $1 billion overstatement of earnings, they said Wednesday.
411904
A higher rate of allergic reactions   and deaths were reported with Bayer AG's heart-surgery drug   Trasylol in 2005, U.S. Food and Drug Administration staff   reviewers said in a report released on Wednesday.
260898
The  world's largest insurance group pays $126m in fines as part of a settlement with US regulators over its dealings with two firms.
149001
AstraZeneca today that CRESTORâ¢ (rosuvastatin), its statin indicated for the treatment of dislipidaemia, has reached the significant milestone of 10 million prescriptions worldwide.
252551
Royal Ahold NV, the Dutch retailer that overstated more than $1 billion of profits, reached a settlement with the US Securities and Exchange Commission, ending a 20-month investigation into accounting fraud.
227799
Drugmakers Merck & Co.  and Schering-Plough Corp.  reported second-quarter results that handily topped Wall Street expectations on Monday, helped by increased sales of the cholesterol-lowering drugs they co-market and other medicines.
687968
German drug and chemical maker Bayer AG said Thursday it posted a third-quarter net profit of 34 million euros ($42.2 million), reversing losses from a year ago as a recovery in the chemical industry helped ...
685313
Boston Scientific Corp. will pay $16.75 million to settle state investigations into flawed heart defibrillators sold by Guidant Corp. , whose substantial legal liability Boston Scientific inherited when it bought the firm last year for $27 billion.
261394
The US division of Germany's Bayer AG agreed to pay a 33 million dollar fine to settle charges it participated in a conspiracy to fix prices of a commonly used chemical for plastics and other goods, US officials said.
157720
WASHINGTON, Feb. 14  â Merck & Company agreed Wednesday to pay $2.3 billion to resolve several tax disputes, the Internal Revenue Service said.